HOME- Hyderabad Conference
- Bryn Mawr Conference
- Workshops & Training
- 2008 Hyderabad
- 2008 Oxford
- 2007 Oxford
- Biggin, P
- Bolger, M
- DiBella, J
- Dudgeon, T
- Gata-Aura, J
- Goodman, J
- Hardy, B
- Hawkins, P
- Kontoyianni, M
- Maginn, S
- Plonka, W
- Reid, D
- Uhrig, U
- 2006 Oxford
- Program
- Exhibition
- Registration
- Jobs
- Contact
- Schedule
|
|
|
|
|
|
|
Dr. Maria Kontoyianni is the Head of Drug Discovery at Crystax Pharmaceuticals, a biotechnology firm located at Barcelona's Science Incubator. In her current role, she oversees research operations, and leads the effort to identify new, potential drug candidates via Crystax's uniquely integrated technology platform and fragment-based screening. She holds a Ph.D. in computational chemistry from the University of North Carolina, Chapel Hill, where she worked under the supervision of Prof. Phil Bowen. After a post-doctoral fellowship with Prof. Terry Lybrand at the University of Washington, she joined Zymo Genetics, a subsidiary of NovoNordisk where she focused on ligand-based design and homology modeling. She then moved to Johnson & Johnson, and Procter & Gamble Pharmaceuticals, where she held positions of increasing responsibility focusing on a range of molecular modeling methods, as applied to various therapeutic targets from hit identification to lead optimization, in particular structure-based design and virtual screening. She is the author of several publications and patents, and also sits on the advisory board of the West Center for Computational Chemistry and Drug Design at University of the Sciences in Philadelphia. She has been an expert evaluator of mobilities FP5 and FP6, and is a contributor to the Practice Standard for Work Breakdown Structures, a publication of the Project Management Institute in Philadelphia.
|
| |
|
|
|
|
|
|
|
|
